drugset / Trial / NCT06775860
ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A randomized, double-blind, placebo-controlled phase III study evaluating the efficacy and safety of oral ICP-332 in subjects with moderate to severe atopic dermatitis
Timeline
- Start
- 2024-11-14
- Primary completion
- 2026-11-25
- Completion
- 2026-12-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ICP-332 | Unknown | — | Oral |